J. Vansteenkiste (Leuven, Belgium), G. Buccheri (Cuneo, Italy)
Gemcitabine (G) or vinorelbine (V)? What's the best drug in combination with a platinium-derivative for the treatment of locally advanced and metastatic non small cell lung cancer (NSCLC)? A 6 years retrospective study M. J. Melo, P. Barradas, M. Cristovao, A. Costa, A. Alves (Lisbon, Portugal)
| |
Gemcitabine plus vinorelbine (GV) or paclitaxel (GT) versus gemcitabine (G) or paclitaxel (T) alone in elderly or unfit nonsmall cell lung cancer (NSCLC) patients. SICOG 9909 phase III trial A. Bianco, G. Frasci, P. Comella, G. De Cataldis, F. Del Gaizo, V. Lorusso, N. Panza, G. Mazzarella, D. Muci, F. Buzzi, A. Gambardella, S. A. Marsico, G. Comella (Naples, Italy)
| |
Low dosage chemotherapy, with carboplatin (CBDCA) and vinorelbine (VNR), in advanced nonsmall cell lung cancer (NSCLC) in patients with low performance status A. Caprioli, G. Bozzola, A. M. Nava, G. Rinaldi, G. F. Tassi (Brescia, Italy)
| |
Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non small cell lung cancer (NSCLC) E. Dimopoulou, A. Agelidou, I. Giozos, Z. Stefanaki, F. Vlastos, E. Tsaroucha, V. Georgoulias (Heraklion, Greece)
| |
Second-line weekly paclitaxel in advanced nonsmall cell lung cancer (NSCLC) G. Buccheri, D. Ferrigno, M. C. Giordano (Cuneo, Italy)
| |
Paclitaxel/carboplatin vs paclitaxel/carboplatin/etoposide as first line treatment in SCLC. A phase III randomized trial K. P. Zarogoulidis, A. Xafenias, A. Xatzopoulou, A. Papagiannis, F. Zoglopitis, E. Fahandidou, T. N. Kontakiotis (Thessaloniki, Greece)
| |
The protective effects of ASA on free radical metabolism in cisplatin induced nephrotoxicity in experimental models B. Ulubas, B. Cimen, D. Apa, E. Saritas, N. Muslu, A. Kanik, O. Cimen (Mersin, Turkey)
| |
Response shift in individual quality of life in patients with lung cancer E. Mannion, D. Waldron, T. Azher, J. J. Gilmartin (Galway, Ireland)
| |